newsfilter
← Latest News
Business Wire·

Agenus Reports 2025 Results; BOT+BAL Advances to Phase 3 and Early Access Programs Expand Globally with Initial Revenues Recognized

Early access programs expand globally: 200+ physician inquiries across 30+ countries; $4.2M in initial program revenue recognized CRC leads BOT+BAL clinical development: 42% two-year overall survival and ~21-month